Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Bristol Myers Squibb Co / Equity Bottom-Up

<ul><li>Bristol-Myers Squibb reported solid financial and operational results for full-year 2025, reflecting steady progress in reshaping its portfolio toward sustained growth.</li><li>The company’s growth portfolio expanded by 17% for the year and 15% in the fourth quarter, nearly offsetting an approximate $4 billion revenue decline in its legacy portfolio.</li><li>Notable contributors were recently launched products including Opdualag, Breyanzi, Camzyos, and Reblozyl—each exceeding $1 billion in full-year sales, with Reblozyl surpassing $2 billion.</li></ul>

Bristol-Myers Squibb reported solid financial and operational results for full-year 2025, reflecting steady progress in reshaping its portfolio toward sustained growth.The company’s growth portfolio expanded by 17% for the year and 15% in the fourth quarter, nearly offsetting an approximate $4 billion revenue decline in its legacy portfolio.Notable contributors were recently launched products including Opdualag, Breyanzi, Camzyos, and Reblozyl—each exceeding $1 billion in full-year sales, with Reblozyl surpassing $2 billion.

ブリストル・マイヤーズ スクイブ：アドミルパラントの肺線維症治療薬としての賭けは、画期的な機会か、それとも臨床上のリスクか？

Bristol Myers Squibb Co

ブリストル・マイヤーズ スクイブ：アドミルパラントの肺線維症治療薬としての賭けは、画期的な機会か、それとも臨床上のリスクか？

ブリストル・マイヤーズスクイブ：アドミルパラントの肺線維症治療薬としての賭けは、画期的な機会か、それとも臨床上のリスクか？